Transfusion therapy: clinical principles and practice
Gespeichert in:
Format: | Buch |
---|---|
Sprache: | English |
Veröffentlicht: |
Bethesda, Md.
AABB Press
2011
|
Ausgabe: | 3. ed. |
Schlagworte: | |
Online-Zugang: | Inhaltsverzeichnis |
Beschreibung: | Includes bibliographical references and index |
Beschreibung: | XXIII, 931 S. Ill., graph. Darst. |
ISBN: | 9781563953071 9783805596961 |
Internformat
MARC
LEADER | 00000nam a2200000zc 4500 | ||
---|---|---|---|
001 | BV037341949 | ||
003 | DE-604 | ||
005 | 20110517 | ||
007 | t | ||
008 | 110415s2011 xxuad|| |||| 00||| eng d | ||
010 | |a 2010037644 | ||
020 | |a 9781563953071 |9 978-1-56395-307-1 | ||
020 | |a 9783805596961 |9 978-3-8055-9696-1 | ||
035 | |a (OCoLC)729980379 | ||
035 | |a (DE-599)BVBBV037341949 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
044 | |a xxu |c US | ||
049 | |a DE-355 | ||
050 | 0 | |a RM171 | |
082 | 0 | |a 615/.39 | |
084 | |a YU 1600 |0 (DE-625)154187: |2 rvk | ||
245 | 1 | 0 | |a Transfusion therapy |b clinical principles and practice |c ed.: Paul D. Mintz |
250 | |a 3. ed. | ||
264 | 1 | |a Bethesda, Md. |b AABB Press |c 2011 | |
300 | |a XXIII, 931 S. |b Ill., graph. Darst. | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
500 | |a Includes bibliographical references and index | ||
650 | 4 | |a Blood |x Transfusion | |
650 | 4 | |a Blood products |x Therapeutic use | |
650 | 4 | |a Anemia |x Treatment | |
650 | 4 | |a Blood Transfusion | |
650 | 0 | 7 | |a Bluttransfusion |0 (DE-588)4007293-9 |2 gnd |9 rswk-swf |
655 | 7 | |0 (DE-588)4151278-9 |a Einführung |2 gnd-content | |
689 | 0 | 0 | |a Bluttransfusion |0 (DE-588)4007293-9 |D s |
689 | 0 | |C b |5 DE-604 | |
700 | 1 | |a Mintz, Paul D. |e Sonstige |4 oth | |
856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022495640&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
999 | |a oai:aleph.bib-bvb.de:BVB01-022495640 |
Datensatz im Suchindex
_version_ | 1804145628547121152 |
---|---|
adam_text | Table
of Contents
Preface
...................................................................xxi
About the Editor
........................................................xxiii
Use of Blood Components in Clinical Practice
1.
The Use of Blood Components Prior to Invasive Bedside Procedures:
A Critical Appraisal
..................................................1
Jamnie
L.
Callum,
MD, FRCPţC),
and Walter
H.
Dzik, MD
Prophylactic Use of Blood Components Before Invasive Procedures
..............2
Assumptions that Underlie the Prophylactic Use of Blood Components
.............3
Specific Bedside Procedures
...............................................10
References
.............................................................29
2.
Red Cell Transfusion Therapy in Anemia
.................................37
Jay E. Menitove, MD
Oxygen Transport Physiology
.............................................38
Physiologic Compensatory Factors Affecting Oxygen Delivery
...................39
Critical Hemoglobin Concentration
.........................................41
Clinical and Experimental Observations in Anemia
............................42
Confounding Factors
.....................................................47
Conclusion
.............................................................49
References
.............................................................50
3.
Transfusion Therapy in Autoimmune Hemolytic Anemia
...................55
Anne E
Eder,
MD, PhD
Warm Autoimmune Hemolytic Anemia
.....................................57
Cold Autoantibodies and Cold Agglutinin Syndrome
...........................69
Autoimmune Hemolytic Anemia with Both Warm and Cold Autoantibodies
.......76
Transfusion
Therapy: Clinical Principles and Practice
Paroxysmal Cold Hemoglobinuria
..........................................76
Drug-Induced Immune Hemolytic Anemia
...................................79
Summary
..............................................................82
References
.............................................................83
4.
Transfusion Therapy in Congenital Hemolytic Anemias
....................87
Bruce I. Sharon, MD
Hemoglobinopaťhies
and Thalassemias
......................................87
Disorders of Red Cell Enzymes
.......................................... 118
Disorders of Red Cell Membranes
........................................ 119
Conclusion
........................................................... 119
References
........................................................... 120
5.
Treatment of Acquired Disorders of Hemostasis
.........................127
Thomas L.
Ortel,
MD, PhD;
Evelyn
Lockhart, MD;
and John E. Humphries, MD
Blood Components and Products
......................................... 128
Hemostatic
Agents
..................................................... 134
Acquired Coagulation Disorders
.......................................... 137
Acquired Coagulation Inhibitors
..........................................151
Conclusion
........................................................... 155
References
........................................................... 155
6.
Treatment of Congenital Coagulopathies
...............................167
Roshni
Kulkami,
MD; Meera Chitlur, MD; and Jeanne M. Lusher, MD
Treatment of Hemophilia A and Hemophilia
В
.............................169
von Willebrand
Disease
................................................ 187
Other Hereditary Disorders of Blood Coagulation
........................... 195
References
...........................................................203
7.
Intrauterine,
Neonatal, and
Pediatric
Transfusion Therapy
...............209
Edward C.C. Wong, MD, and Wendy Paul, MD
Fetuses as Transfusion Recipients
........................................209
Neonates
as Transfusion Recipients
.......................................225
Transfusion Beyond the Neonatal Period
..................................239
Summary
............................................................251
References
...........................................................251
8.
Transfusion Therapy in Surgery
.......................................265
Richard
К
Spence, MD,
MHA,
FACS
Recent Trends
........................................................265
Red Biood Cells in Surgery
..............................................266
Xli
Table
of
Contents
Transfusion
in Trauma
..................................................276
Risks of
Transfusion
....................................................279
Avoidance of Transfusion
................................................283
Platelets, Fresh Frozen Plasma, and Cryoprecipitate in Surgery
.................290
Conclusion
............................................................291
References
............................................................292
9.
Massive Transfusion and Transfusion Therapy in Trauma
................305
John R. Hess, MD, MPH, FACP, FAAAS;
Pär
I. Johansson, MD,
МРА;
and
John B. Holcomb, MD, FACS
Approach to Severely Injured Patients
.....................................306
The Acute Coagulopathy of Trauma and Shock
..............................308
Military Surgical Experience
..............................................312
Other Experience and Studies
............................................313
Who Needs Damage- or Hemorrhage-Control Resuscitation?
...................314
The Lack of Level I Evidence
............................................315
The Need for Better Hemorrhage-Control Products
...........................316
Massive Transfusion Protocols
............................................317
Conclusions
...........................................................318
References
............................................................318
10.
Transfusion Therapy in Critical Care
....................................323
Thinesh Dahanayake, MD; Patricia Janet
Sime,
MD, FRCP;
Richard Phipps, PhD; and
Neil Blumberg, MD
Causes of Anemia in the ICU
.............................................324
RBC Transfusion in the ICU
..............................................324
Risks of Transfusion
....................................................328
Emergency Transfusions
...............................-----..............330
Decreasing the Need for Transfusion
......................................331
Platelet Transfusion
.....................................................332
FFP
Transfusions
.......................................................334
Conclusion
............................................................335
References
............................................................335
11.
Transfusion Practice in Solid Organ Transplantation
.....................339
Glenn Ramsey, MD, and Paul D. Mintz, MD
Best-Accepted Practices
.................................................340
Transfusion Support
....................................................342
Areas of Interest
...........................................·...........344
Immunohematologic Considerations
.......................................345
Allograft Donor Infectious Disease Testing
..................................348
References
............................................................350
Transfusion
Therapy: Clinical Principles and Practice
12.
Transfusion Therapy in Therapeutic Apheresis
..........................355
Gay Wehrli, MD, MSEd
Overview of Therapeutic Apheresis
.......................................363
Therapeutic Apheresis Modalities
........................................364
Replacement Fluids for Therapeutic Apheresis
..............................377
Patient Evaluation
.....................................................380
Patient Preparation
....................................................382
Procedure Complications
................................................384
Conclusion
...........................................................387
References
...........................................................387
Appendix
12-1.
Table of Predicted Normal Blood Volumes in Men
...........392
Appendix
12-2.
Table of Predicted Normal Blood Volumes in Women
........393
Appendix
12-3.
Example of a Therapeutic Apheresis Service Consultation Form
. 394
Blood Components and Derivatives
13.
Platelet Transfusion Therapy
..........................................397
Deborah Sesok-Pizzini, MD, MBA, and Jay H. Herman, MD
Platelet Products
......................................................398
Platelet Refractoriness: Etiology, Prevention, and Management
................404
Indications for Platelet Transfusion
.......................................406
Transfusion Threshold and Prophylactic Transfusion
........................412
Assessment and Dose
..................................................413
Selected Adverse Events: Bacterial Contamination, Pathogen Reduction, and
Alloimmunization
..................................................421
Platelet Additive Solutions
..............................................422
Red Blood Cell Transfusion for Thrombocytopenic and Thrombocytopamic
Bleeding
..........................................................424
Conclusion
...........................................................425
References
...........................................................426
14.
Granulocyte (Neutrophil) Transfusion Therapy
..........................433
Ronald G. Strauss, MD
Therapeutic Granulocyte (Neutrophil) Transfusions
..........................434
Prophylactic Granulocyte (Neutrophil) Transfusions
..........................441
Methods for PMN Collection and Transfusion
...............................443
References
...........................................................445
15.
Immune Globulin Therapy
............................................449
E. Richard Stiehm, MD
Animal Sera and
Antitoxins.............................................449
Table
of
Contents
Human Immunoglobulins
................................................453
Intramuscular Immune Globulin
..........................................454
Intravenous Immunoglobulin
.............................................455
Subcutaneous Immunoglobulin
...........................................462
Advantages and Disadvantages of IGSC
....................................463
Effectiveness of IGIV or IGSC in Primary Antibody Deficiencies
...............463
IGIV or IGSC in Combined Immunodeficiencies
.............................463
IGIV in Secondary Antibody Deficiencies
...................................463
Immunoglobulin Therapy in Infection
......................................466
IGIV in Inflammatory and Autoimmune Disorders
...........................471
Monoclonal Antibodies
..................................................477
Special Immunoglobulins for Noninfectious Use
..............................481
Immunoglobulin Use by Unusual Routes
...................................481
Future Directions
.......................................................482
References
............................................................482
16.
Rh Immune Globulin
..................................................493
Paul D. Mintz, MD
Overview of RhIG Use
.................................................494
Testing and Treatment of Women Who Are Pregnant or Have Been
Pregnant Recently
...................................................495
Antenatal Fetal
D
Genoryping
............................................497
Testing the Father
......................................................499
Dose of RhIG
..........................................................499
Failure of Prophylaxis
...................................................500
Risks of RhIG Administration
.............................................501
Special Circumstances
...................................................502
Prevention of
D
Alloimmunization after Transfusion of D-Positive
Red Cells
..........................................................504
Conclusion
............................................................508
References
............................................................508
17.
Clinical Uses of Fibrin Sealant
..........................................511
William D. Spotnitz, MD, MBA
Abdominal Surgery
.....................................................513
Cardiovascular Surgery
..................................................516
Dental Surgery
.........................................................518
Head and Neck Surgery
.................................................518
Neurosurgery
..........................................................519
Obstetric and Gynecologic Surgery
........................................521
Oncology Surgery (Breast and Inguinal Dissection Procedures)
.................521
Ophthalmologic Surgery
.................................................522
Orthopedic Surgery
.....................................................523
Transfusion
Therapy: Clinical Principles and ftactice
Plastic Surgery
........................................................524
Thoracic Surgery
......................................................525
Urologie
Surgery
......................................................526
Vascular Surgery
......................................................527
Conclusion
...........................................................527
References
...........................................................527
18.
Transfusion Therapy in Hematopoietic Progenitor and Stem Cell
Transplantation
...................................................539
Richard
С
Friedberg,
MD, PhD, FCAP, and Chester Andrzejeivskijr, PhD,
MD,FCAP
Provision of Blood Components
..........................................540
Modifications to Blood Components
.......................................548
Hematopoietic Progenitor Cell Products
...................................552
Conclusion
...........................................................552
References
...........................................................553
19.
Lymphocytes as Transfusion Immunotherapy
...........................559
Hanh M. Khuu, MD, and Harvey G. Klein, MD
Introduction
..........................................................560
Lymphocytes, Minimally Manipulated
.....................................562
Lymphocytes, More than Minimally Manipulated
............................567
Regulatory Considerations
..............................................571
References
...........................................................572
20.
The Role of Hematopoietic Growth Factors in Transfusion Medicine
......583
Carolyn F. Whitsett,MD
Erythropoiesis Stimulating Agents
........................................ 584
Myeloid Growth Factors
................................................ 604
Clinical Indications
..................................................... 606
Thrombopoiesis Stimulating Agents
....................................... 611
Conclusion
........................................................... 615
References
........................................................... 615
Appendix
20-1.
NCCN Guidelines on Myeloid Growth Factors
................ 626
21.
Alloimmunization to Red Cell Antigens and Management of
Alloimmunized Patients
............................................631
James C. Zimring, MD, PhD, and Steven L. Spitalnik, MD
Induction of Alloantibodies by Red Cell Transfusion
.........................632
Management of Alloimmunized Patients
...................................637
Summary
............................................................640
References
...........................................................640
XVI
Table
of
Contents
Preventing and Managing Adverse Events
22.
Transfusion-Associated Graft-vs-Host Disease
............................643
Jed B. Gorlin, MD, and Paul D. Mintz, MD
History
...............................................................643
Clinical Manifestations
...................................................644
Irradiation
............................................................645
General Indications for Irradiation
.........................................649
Which Components May Cause TA-GVHD?
................................649
Indications for Irradiating Cellular Blood Components
........................649
Alternatives to Irradiation
................................................656
Conclusion
............................................................657
References
............................................................657
23.
Leukocyte-Reduced and Cytomegalovirus-Reduced-Risk
Blood Components
.................................................665
Pamela Clark, MDJD, and John P. Miller, MD, PhD
Leukocyte Reduction: Definition, Mechanisms, Timing, and Potential Adverse
Effects
.............................................................665
Febrile Nonhemolytic Transfiision Reactions
................................667
Prevention of Alloimmunization and Platelet Refractoriness
....................669
Use of Cytomegalovirus-Reduced-Risk Blood Components
....................673
Transfusion-Related Immune Modulation
...................................680
Practical Considerations
.................................................686
Summary
.............................................................687
References
............................................................687
24.
Alternatives to Allogeneic Transfusion in Patients with Surgical Anemia.
.. .699
Lawrence T. Goodnough, MD
Perioperative Autologous
Blood Donation and Transfusion
....................699
Pharmacologie
Interventions to Reduce AUogeneic Blood Transfusion
...........707
Conclusion
............................................................714
References
............................................................715
25.
Pathogen Reduction Techniques
........................................721
Joseph P.
R
Pelletier,
MD, and Christopher A. Tormey, MD
Overview
.............................................................721
Solvent/Detergent Treatment
.............................................724
Methylene
Blue
........................................................728
Amotosalen
...........................................................731
FRALE
...............................................................736
PENI
10..............................................................737
XVII
Transfusion
Therapy: Clinical Principles and Practice
Riboflavin
............................................................741
Clinical Trials of Pathogen-Reduced Blood Components
......................744
Transfusion-Associated Graft-vs-Host Disease
...............................749
Conclusion
...........................................................750
References
...........................................................750
26.
Management of
Transfusion
Reactions
.................................757
Robertson D. Davenport, MD
Febrile Nonhemolytic Reactions
..........................................757
Allergic Reactions
.....................................................762
Severe Allergic (Anaphylactic) Reactions
...................................763
Acute Hemolytic Reactions
..............................................764
Delayed Hemolytic Reactions
............................................767
Bacterial Contamination of Blood Components
.............................769
Transfusion-Related Acute Lung Injury
....................................770
Posttransfusion Purpura................................................
772
Graft-vs-Host Disease
...................................................773
Hypotensive Reactions
.................................................773
Nonimmune Hemolysis
.................................................774
Transfusion-Associated Circulatory Overload
...............................775
Transfusion-Related Hypothermia
........................................776
Transfusion-Related Hyperkalemia
.......................................777
Transfusion-Related Acid-Base Abnormalities
..............................777
Acute Pain Transfusion Reaction
.........................................778
References
...........................................................778
Quality in Transfusion Practice
27.
Administration of Blood
Componente
..................................785
Joanne L. Becker, MD
Preadministration Issues
................................................785
Blood Administration
..................................................787
Current Practices
......................................................792
Conclusion
...........................................................794
References
...........................................................794
28.
Hemovigilance: An Approach to Risk Management in Transfusion
Medicine
.........................................................797
Cees
Th. Smit
Sibinga, MD, PhD, FRCPEdin, FRCPath, and
Michael
E
Murphy,
MD, FRCP,
FRCPath
Overview of Hemovigilance
.............................................798
Public Health Objectives
................................................798
Table
of
Contents
Transfusion Chain
......................................................799
Transfusion Reactions
...................................................800
Transfusion
Quality
System
..............................................802
Classification
of
Adverse
Events to
Transfusion
..............................802
Organizational
Structure
and Levels of Reporting
............................803
Use
of Data by the French and UK Hemovigilance Systems to Reduce
Adverse Events Associated with Transfusion
.............................804
Contribution of Hemovigilance to Public Health
.............................808
Implementation
........................................................809
Most Commonly Encountered Difficulties
...................................810
Conclusion
............................................................810
References
............................................................810
29.
Quality Assessment and Improvement of Blood Transfusion Practices
......813
Paul D. Mintz, MD
History
...............................................................815
Errors in Transfusion Practice
............................................815
Accreditation and Regulatory Requirements
................................817
The Transfusion Committee
..............................................818
Conclusion
............................................................832
References
............................................................832
30.
Overview of Medical-Legal Issues in Transfusion Medicine
in the United States
................................................837
Hon. Edward D. Bronfin and Pamela Clark, MD,JD
Applicable Legal Principles
...............................................837
Strict Products Liability/Breach of Warranties and Blood Shield Laws
...........838
Summary
.............................................................850
References
............................................................851
Appendix
30-1.
Blood Shield Laws as of May
2010..........................853
Summation
31.
To Transfuse or Not to Transfuse: An Assessment of Risks and Benefits
-----855
Manan
Petrides, MD, and James P. AuBuchon, MD
Noninfectious Risks of Transfusion
........................................855
Infectious Risks of Transfusion
............................................863
Indications for Transfusion
...............................................875
Conclusions
........................................·..................888
References
............................................................889
Index
....................................................................901
|
any_adam_object | 1 |
building | Verbundindex |
bvnumber | BV037341949 |
callnumber-first | R - Medicine |
callnumber-label | RM171 |
callnumber-raw | RM171 |
callnumber-search | RM171 |
callnumber-sort | RM 3171 |
callnumber-subject | RM - Therapeutics and Pharmacology |
classification_rvk | YU 1600 |
ctrlnum | (OCoLC)729980379 (DE-599)BVBBV037341949 |
dewey-full | 615/.39 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 615 - Pharmacology and therapeutics |
dewey-raw | 615/.39 |
dewey-search | 615/.39 |
dewey-sort | 3615 239 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
edition | 3. ed. |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01632nam a2200457zc 4500</leader><controlfield tag="001">BV037341949</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20110517 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">110415s2011 xxuad|| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2010037644</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781563953071</subfield><subfield code="9">978-1-56395-307-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783805596961</subfield><subfield code="9">978-3-8055-9696-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)729980379</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV037341949</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM171</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.39</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YU 1600</subfield><subfield code="0">(DE-625)154187:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transfusion therapy</subfield><subfield code="b">clinical principles and practice</subfield><subfield code="c">ed.: Paul D. Mintz</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">3. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bethesda, Md.</subfield><subfield code="b">AABB Press</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIII, 931 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood</subfield><subfield code="x">Transfusion</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood products</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anemia</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood Transfusion</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bluttransfusion</subfield><subfield code="0">(DE-588)4007293-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4151278-9</subfield><subfield code="a">Einführung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Bluttransfusion</subfield><subfield code="0">(DE-588)4007293-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mintz, Paul D.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022495640&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-022495640</subfield></datafield></record></collection> |
genre | (DE-588)4151278-9 Einführung gnd-content |
genre_facet | Einführung |
id | DE-604.BV037341949 |
illustrated | Illustrated |
indexdate | 2024-07-09T23:22:28Z |
institution | BVB |
isbn | 9781563953071 9783805596961 |
language | English |
lccn | 2010037644 |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-022495640 |
oclc_num | 729980379 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | XXIII, 931 S. Ill., graph. Darst. |
publishDate | 2011 |
publishDateSearch | 2011 |
publishDateSort | 2011 |
publisher | AABB Press |
record_format | marc |
spelling | Transfusion therapy clinical principles and practice ed.: Paul D. Mintz 3. ed. Bethesda, Md. AABB Press 2011 XXIII, 931 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index Blood Transfusion Blood products Therapeutic use Anemia Treatment Bluttransfusion (DE-588)4007293-9 gnd rswk-swf (DE-588)4151278-9 Einführung gnd-content Bluttransfusion (DE-588)4007293-9 s b DE-604 Mintz, Paul D. Sonstige oth Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022495640&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
spellingShingle | Transfusion therapy clinical principles and practice Blood Transfusion Blood products Therapeutic use Anemia Treatment Bluttransfusion (DE-588)4007293-9 gnd |
subject_GND | (DE-588)4007293-9 (DE-588)4151278-9 |
title | Transfusion therapy clinical principles and practice |
title_auth | Transfusion therapy clinical principles and practice |
title_exact_search | Transfusion therapy clinical principles and practice |
title_full | Transfusion therapy clinical principles and practice ed.: Paul D. Mintz |
title_fullStr | Transfusion therapy clinical principles and practice ed.: Paul D. Mintz |
title_full_unstemmed | Transfusion therapy clinical principles and practice ed.: Paul D. Mintz |
title_short | Transfusion therapy |
title_sort | transfusion therapy clinical principles and practice |
title_sub | clinical principles and practice |
topic | Blood Transfusion Blood products Therapeutic use Anemia Treatment Bluttransfusion (DE-588)4007293-9 gnd |
topic_facet | Blood Transfusion Blood products Therapeutic use Anemia Treatment Bluttransfusion Einführung |
url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022495640&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT mintzpauld transfusiontherapyclinicalprinciplesandpractice |